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Abstract 
 
Objectives: The objectives of this investigation were to investigate the effectiveness and longevity 
of an oral rinse product containing 0.10% (w/v) of the chlorine dioxide precursor sodium chlorite 
(1) on oral malodour in participants throughout a 12 hr. daylight diurnal cycle.  
 
Materials and Methods: 30 Healthy participants (17 male, 13 female) were recruited to the study. 
Volatile sulphur compound levels [VSCs: H2S, CH3SH and (CH3)2S] were simultaneously 
monitored in their oral cavity air samples both before (0 hr.) and at 0.33, 4.00, 8.00 and 12.00 hr. 
after using the above oral rinse, or water as a negative control (participants refrained from oral 
hygiene measures during this 12 hr. period). The experimental design for this cross-over 
investigation was a mixed model ANOVA-based system incorporating treatments, sampling time-
points and participants, together with their first-order interactions, as components of variance.  
 
Results: Results acquired demonstrated that the oral rinse formulation effectively suppressed VSC 
production in the oral environment for 12 hr. periods (p < 0.0001, 0.0001 and 0.002 for H2S, 
CH3SH and (CH3)2S respectively). Mean 0 vs 12.00 hr. reductions in oral cavity H2S and CH3SH 
concentrations were much greater than those observed for the H2O negative control (p < 10
-8), 
but not so for (CH3)2S.  Principal component analysis (PCA) a H2S/CH3SH linear combination 
and (CH3)2S alone significantly loaded on the first and second separate orthogonal components 
respectively, an observation confirming differing sources for these variable sets.        
Conclusions: The oral rinse explored effectively blocked VSC production in the oral cavity for a 
period of 12 hr. This extended efficacy duration is likely to be ascribable to the ability of its active 
ClO2
- ingredient to exert a combination of biochemical (direct VSC- and amino acid VSC 
precursor-consuming) and microbicidal actions in vivo.   
Clinical Relevance: The 12 hr. longevity of product (1)’s oral malodour-neutralising actions is of 
much clinical significance in view of the involvements of VSCs, particularly CH3SH, in the 
pathogenesis of gingivitis and periodontitis.   
(1): Ultradex™ oral rinse, Venture Life Group plc, UK. 
 
Keywords: Oral Malodour; Volatile Sulphur Compounds; Oral Rinse; Sodium Chlorite; 
Longevity of Oral Rinse Action. 
 
Running Title: Twelve hour VSC-neutralising longevity of an oral rinse formulation 
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1. INTRODUCTION 
Oral malodour (halitosis, bad breath) is a common, socially disturbing and recurring condition 
which primarily affects a large percentage of the adult global population [1]. Cases of this very 
disturbing disorder are generally ascribable to microbial putrefaction within the oral cavity (usually 
within anaerobic sites) [2,3], and this process generates malodorous volatile sulphur compounds 
(VSCs), which are predominantly composed of hydrogen sulphide (H2S), methyl mercaptan 
(CH3SH) and dimethyl sulphide (CH3SCH3) [1,4]. Limited salivary flow rates, periodontal diseases, 
excessive bacterial colonisation of the tongue, unclean dentures, and poor or unsuitable dental 
restorations can trigger halitosis of oral aetiology [5-11], although upper and lower respiratory tract 
conditions, a series of systemic diseases, and gastrointestinal and neurological diseases, together 
with the therapeutic application of selected drugs, are common non-oral aetiologies [12]. 
Therefore, a broad spectrum of clinical conditions, oral or otherwise, can give rise to oral malodour 
which can be monitored by a range of strategies.  
The above VSCs are derived from the putrefaction of cysteine- and methionine-containing 
proteins, predominantly by gram-negative micro-organisms. Optimum putrefactive activity occurs 
in a low carbohydrate environment, at physiological pH and temperature values, and also in 
anaerobic loci. Salivary sediment containing exfoliated epithelial cells acts as a primary substrate 
with a predominantly ‘oxidised’ status (i.e. a high disulphide:thiol concentration ratio). Proteolysis, 
coupled with a reduction of disulphide bonds, precedes the development of VSC-based oral 
malodour [1,13].  
Determinations of the nature and magnitude of oral malodour demand reliable, sensitive, accurate 
and precise experimental techniques, and previously reported methods available for its monitoring 
include (1) organoleptic (subjective) systems [14,15]; (2) measurement of VSCs via gas 
chromatography (GC) coupled with flame-photometric detection [16]; (3) a combination of (1) 
and (2) above [13]; (4) cryo-osmoscopy [17]; or (5) the time-consuming culture of plaque and 
periodontal pocket exudates in selected bacteriological media [10]. However, to date only a limited 
amount of experimental data are available on the applications and reproducibilities of such 
approaches, and considerations including the menstrual cycle, heterogeneity in oral hygiene 
control, circadian variation, smoking habits and climate may indeed exert an influence on results 
acquired from such studies [18]. Moreover, following the evacuation of malodorous gases in the 
oral cavity, the rate and extent of their restoration to this environment are of considerable debate.  
Further pioneering reports have outlined the applications of a portable industrial H2S/CH3SH-
specific VSC monitor (halimeter) [19,20], and highly significant correlations between these 
measurements and corresponding organoleptic ratings performed by a total of 7 judges have been 
found [19]. This electrochemical VSC monitor involves a voltammetric sensor which draws a 
sample of oral gas across an electrocatalytic sensing electrode operating at a potential of +0.50 V, 
a value sufficient to ensure the complete oxidation of electron-donating thiols, specifically CH3SH 
and H2S [in general, redox potentials (Eo) of thiol/disulphide couples lie in the -0.20 to +0.40V 
range]. Such electrochemical reactions generate an electric current, the magnitude of which is 
directly proportional to the total chemically-reducing, gaseous VSC concentrations. This current 
is converted to a voltage which, in turn, is then transferred to a meter which provides VSC 
concentrations in parts-per-billion (ppb) throughout a range of 0-1000 ppb. Determinations 
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performed using this device have been shown to be more precise and reproducible than those 
obtained by subjective, organoleptic panel methods, and more sensitive to decreases in VSC levels 
arising from treatment with a number of oral healthcare products (OHCPs) [19,21].  
Recently, a more specific, portable gas chromatographay-based VSC measurement device has been 
developed (OralChroma™, Abimedical Corporation, Miyamae-ku Kawasaki-shi, Kanagawa, 
Japan, reviewed in [22]). This facility has the ability to determine the oral cavity ppb concentrations 
of H2S, CH3SH and CH3SCH3 simultaneously in air directly sampled from the oral cavity, and 
displays each level on a convenient display panel (each of these VSC agents and their oral cavity 
concentrations may, at least in principle, be correlated with a specific cause of halitosis). 
Additionally, this VSC monitor offers many bioanalytical benefits over more complex GC 
methods, and these include substantially lower costings, rapid sample throughput, ready 
portability, facile point-of-care, ‘on-site’ use, no major requirements for the involvement of 
specialist technical staff, and the suitability of the means by which oral cavity air samples are 
collected.  
Both chlorine dioxide (ClO2
•) and its precursor chlorite anion (ClO2
-) are very effective in 
oxidatively consuming VSCs, and also their sulfur-containing amino acid precursors within the 
oral cavity [23]. Indeed, the latter is now a key ingredient in selected oral rinse formulations widely 
available commercially as ‘over-the-counter’ products such as (1). Two previously conducted 
investigations focused on an evaluation of the efficacy of an oral rinse product containing 0.10% 
(w/v) ‘stabilised’ ClO2
• (predominantly ClO2
-) on oral soft tissues and gingivitis found that it 
effectively improved periodontal health. Specifically, this formulation substantially reduced 
‘bleeding-on-probing’ in patients with gingivitis [24], and gave rise to a healing of > 67% of 
periodontal pockets [25]. Moreover, further studies have explored the microbicidal actions of such 
products [26,27], and Mohammed et al. [28] assessed their effectiveness towards the clinical control 
of chronic atrophic candidiasis.   
Additional studies have clearly demonstrated that such ClO2
--containing products are efficacious 
in the treatment of oral malodour in vivo [26-29,30]. Although the VSC-neutralising activities of 
ClO2
- are beyond dispute, both in vitro and in vivo, considerable debate remains regarding the 
longevity of these actions. For example, although Shinada et al. [29] monitored the effectiveness 
of an oral rinse product containing 0.16% (w/v) of this oxyhalogen oxidant, VSCs were only 
monitored for periods of up to 4.0 hr. Therefore, in this investigation, we have explored the clinical 
effectiveness of an oral rinse product (1), tested against a water placebo treatment, against oral 
malodour (halitosis) using the above portable gas-chromatographic monitoring system. These VSC 
determinations were made before, and at selected diurnal time-points after treatment of 
participants with each of the oral rinse formulations in the recommended manner and compared 
with corresponding measurements made after they rinsed with a H2O placebo control in place of 
the oral rinse formulation. The total (daily) period of each testing was 12.00 hours in order to 
determine the capacity of this oral rinse product to combat oral malodour for this prolonged time 
length. 
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2. MATERIALS AND METHODS 
 
2.1 Volatile Sulphur Compound (VSC) Determinations 
Measurements of each VSC were made on an OralChroma™ portable gas chromatographic 
monitoring system. Participants were required to refrain from talking for 5 min. prior to 
measurement, and also to breathe through their noses during the collection of oral cavity air 
samples via a syringe; a 1.00 ml volume of air was sampled, and exactly 0.50 ml of each sample 
was injected into the OralChroma™ device. The time period between air sampling and gas 
chromatographic analysis was ≤ 5 seconds. Results were recorded as parts-per-billion (ppb) oral 
cavity VSC concentrations.  
 
2.2 Participant Population 
This investigation involved 30 non-smoking human volunteers (17 male, 13 female) ranging in 
age from 24 to 55 years. Written informed consent was acquired from all participants, and this 
investigation was performed in accordance with the Declaration of Helsinki of 1975 (revised in 
1983). It was approved by the Faculty of Health and Life Sciences Research Ethics Committee, 
De Montfort University, Leicester UK (reference number 1117). During the recruitment stages of 
the investigation, participants were supplied with a Participant Information Sheet and, if agreeing 
to take part in the investigation, were subsequently required to sign a University Research Ethics 
Consent Form. All participants recruited were also required to complete a short questionnaire 
which requested essential information, including medical history, age, gender, body mass index 
(BMI), dental treatment history and any current medication that they were receiving. 
 
2.3 Exclusion Criteria 
Participants were excluded from the investigation if they had any serious or chronic medical 
condition such as diabetes, cardiovascular diseases or cancer, periodontal diseases, or any other 
condition which precluded their participation in the trial. Those receiving any form of medication 
during the 7 days prior to the first testing day were excluded from the investigation. All participants 
were also instructed not to receive any form of medication during the two sampling test days of 
the trial conducted. 
 
2.4 Oral Rinse Composition 
Oral rinse product (1) contained sodium chlorite (Na+/ClO2
-) at an added level of 0.10% (w/v), 
i.e. 1.106 x 10-2 mol.dm-3; 0.20% (w/v) trisodium phosphate, as Na3PO4.12H2O (5.26 x 10
-3 
mol.dm-3); and 0.079% (w/v) citric acid (4.11 x 10-3 mol.dm-3). The pH value of this product was 
6.50.  
 
2.5 Evaluations of the Abilities of Oral Rinse Products to Combat Oral Malodour 
Participants were required to rinse with the oral rinse formulation (15 ml volumes of oral rinse (1)) 
for a period of 30 seconds. Each participant was also required to rinse with an equivalent volume 
of tap water on a separate trial day, this treatment serving as a placebo control. Primarily, 
participants were provided with a standard NaF-containing toothpaste (Colgate Triple Cool Stripe, 
Colgate Palmolive) and allowed to brush with it (each using a standard Colgate Extra Clean 
toothbrush) as usual in place of their usual oral healthcare regimen for a period of 7 days (2 x daily) 
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in order to establish ‘baseline’ oral cavity VSC data. Participants were randomly allocated to either 
the primary phase I, pre-crossover oral rinse or negative H2O control groups using a computerised 
random number generator. Prior to the testing periods for the oral rinse or H2O placebo control 
treatments investigated (12.00 hr. in total), each participant was requested to refrain from oral 
activities (i.e., eating, drinking, tooth-brushing, oral rinsing, etc.) for a period of at least 4.0 hr. VSC 
levels were determined both prior to (0.00 hr.) and following oral rinsing episodes with the oral 
rinse or H2O placebo control examined (0.33, 4.00, 8.00, and 12.00 hr. post-administration, 
together with immediate subsequent measurements made following each of those above, so that 
there was a total of 9 determinations made per participant per diurnal trial period, i.e. at 0.00, 2 x 
0.33, 2 x 4.00, 2 x 8.00, and 2 x 12.00 hr. subsequent to therapeutic application of oral rinse 
treatments or the H2O placebo).  
 
The first (baseline) measurement was made at 10.00 am, and all participants were required to agree 
to avoid their early morning breakfast meal [and, of course, all further oral activities 4.0 hr. prior 
to the collection of this first (zero control) sample] on each of the two days in which they were 
involved in the investigation. Administration of the oral rinse or H2O control to each of the 30 
participants was staggered throughout time, and the minimum ‘washout’ period between the single 
product administered and the H2O placebo was 4 days prior to crossing over to the other available 
treatment regimen. During these ‘washout’ periods, it was ensured that all participants were 
maintained on the twice-daily oral healthcare tooth-brushing regimen with the standard, NaF-
containing toothpaste. Participants were blinded (i.e. unaware of the nature of the oral rinse or 
water placebo treatments that they were receiving),   since both treatments were provided in coded 
sterile dispensing containers. Time-dependent VSC determinations were performed on a single 
participant per day using the same OralChroma™ monitoring device.      
 
As an additional precaution, throughout the 12.00 hr. total testing period, participants were 
instructed to avoid the consumption of foods that have a strong odour such as onions, garlic, 
selected further vegetables (e.g. chillies and peppers), nuts, cheese, fish etc., especially spicy foods 
such as curries, together with certain drinks, especially coffee and alcoholic beverages (the taste 
and smell of such foods and beverages lingers on the breath long after their consumption), and 
which may therefore exert effects on the oral cavity VSC measurements made (when consumed 
and digested, odorous and malodorous agents derived from these foods are absorbed into the 
bloodstream and then transported to the lungs: this allows the odour associated with them flow 
from the mouth area during the exhalation process).  
 
2.6 Experimental Design for the Study and Statistical Analysis of Oral Cavity VSC 
Concentrations 
For each of the above clinical datasets, we employed analysis of variance (ANOVA)-based   
experimental designs. These procedures were employed to determine the significance of the 
‘Between-Treatments’ and ‘Between Diurnal Time-Points’ effects incorporated into the study, and 
also the further components of variances (CVs) involved, specifically that ‘Between-Participants’, 
together with those arising from the Treatment x Diurnal Time-Point, Treatment x Participant and 
Participant x Diurnal Time-Point interaction effects. 
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Hence, the overall experimental design for this investigation was classified as a mixed model, 2 
factor system with treatments (one oral rinse, together with the water placebo control) and time-
points at which the measurements were made being fixed effects at 2 and 5 levels respectively, and 
participants (n = 30 in total) being a random effect. This mixed model component analysis for 
each VSC determined therefore comprised the 3 main effect factors, their associated interactions, 
and fundamental error.  
 
However, a total of four different ANOVA-based analysis models were employed. In the first of 
these (model 1), the oral rinse (1) and water placebo treatment groups were partitioned, and   each 
‘Treatment’ dataset was analysed separately so that the significance of modifications to oral cavity 
VSC levels could be evaluated at all post-treatment time-points for each of these treatments 
(equation 1). The second (model 2) involved a consideration of the above 3 main factors, but 
without inclusion of all the above first-order interaction components of variance (equation 2), 
whereas the third (model 3) was represented by model 2 with the incorporation of all three of 
these first-order interaction effects (equation 3). In these equations, Si, Pj, Tj, SPij, STik, PTjk and 
eijkl represent the ‘Between-Sampling Time-Point’, ‘Between-Participant’, ‘Between-Treatment’, 
Sampling Time-Point x Participant interaction, Sampling Time-Point x Treatment, Participant x 
Treatment interaction and unexplained error sources of variation, respectively.     
     
yijl = Si + Pj + SPij + eijl    (1) 
 
yijkl = Si + Pj + Tk + eijkl    (2) 
 
yijkl = Si + Pj + Tk + SPij + STik + PTjk + eijkl    (3) 
 
Finally, the fourth model (model 4) featured only the ‘Between-Treatments’ and ‘Between-
Participants’ main effects, and also the Treatment x Participant interaction one as explanatory 
variables, and the difference observed between the 0.00 control and 12.00 hr. diurnal time-points 
for each participant served as the dependent variable analysed (equation 4).  
 
yjkl = Pj + Tk + PTjk + ejkl     (4)  
 
For all models, Bonferroni-corrected post-hoc ANOVA analysis was performed to test the 
significance of individual comparisons between pairs of sampling time-points and participants.  
 
Datasets were generalised logarithm (glog)-transformed and normalised (i.e., centered and 
autoscaled), and these transformed/normalised datasets were analysed as described above. 
 
Further experimental design models were employed to further explore participant-matched 
differences between the mean oral cavity VSC levels of the two treatment groups at both the 
baseline 0.00 hr. and final 12.00 hr. diurnal trial time-points. 
 
ANOVA of our experimental data according to each of the above experimental designs was 
performed using XLSTAT2014 software. Pearson and multivariate partial correlations between 
each of the three VSCs determined were also explored using this software, as was multivariate 
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analysis of variance (MANOVA) and principal component analysis (PCA). Pearson correlations 
between the participants’ baseline 0.00 hr. and 12.00 hr. diurnal trial time-point VSC 
concentrations were also investigated with this software package. PCA analysis was employed to 
investigate inter-relationships between each of the 3 VSCs monitored, and featured Varimax PC 
rotation with Kaiser normalisation. A maximum of 2 factors was considered, and a PC loading 
vector value of 0.40 was considered as the minimum required for a significant contribution towards 
each PC isolated. Further multivariate analysis was conducted with MetaboAnalyst 3.5 software.    
 
3. RESULTS 
 
With our model 1 ANOVA analysis (as detailed in section 2), application of the 0.10% (w/v) 
sodium chlorite-containing oral rinse formulation (1) as a treatment for oral malodour gave rise to 
extremely highly significant differences between the mean oral cavity H2S and CH3SH 
concentrations between the 0.00 hr. (pre-treatment) time-point and those at 0.33, 4.00, 8.00 and 
12.00 hr. post-treatment ones (p = 1.81 x 10-13 and 2.54 x 10-17 for these VSCs respectively), 
specifically substantial reductions in their post-treatment oral cavity concentrations. For (CH3)2S, 
however, there were only highly significant time-dependent decreases from its mean 0.00 hr. oral 
cavity level observed at the 0.33, 8.00 and 12.00 hr. post-treatment time-points (p = 2.57 x 10-8). 
However, no significant differences were observed in the mean concentrations of this VSC 
between the 0.00 and 4.00 hr. time-points. 
 
Therefore, for model 1, experimental data acquired clearly confirm that the oral malodour-
neutralising effects of the oral rinse product tested are significantly prolonged to the 12.00 hr. post-
administration time-point for each VSC, although such alleviations in oral cavity air VSC 
concentrations are less clear for (CH3)2S in this context. The Diurnal Time-Point x Participant 
interaction effect was also statistically significant for each VSC monitored (p = 4.60 x 10-3, 9.23 x 
10-8 and 5.10 x 10-3 for H2S, CH3SH and (CH3)2S respectively), and this confirms that the sampling 
time-point dependence of the patterns of oral cavity VSC level responses to treatment with oral 
rinse (1) differed markedly between participants.   
 
For the water placebo treatment, significant differences were found only between the 0.00 and 
each of the 4.00, 8.00 and 12.00 hr. time-point mean values for both H2S and CH3SH (p < 4.11 x 
10-14 and 3.36 x 10-8 respectively), and only the 0.00 and 12.00 hr. time-point mean values for 
(CH3)2S (p = 1.23 x 10
-7); there were no statistically significant differences found between the 0.00, 
0.33, 4.00 and 8.00 hr. time-points for this blood source VSC. As expected, the Diurnal Time-
Point x Participant interaction effect was again statistically significant for each VSC monitored (p 
= 9.70 x 10-3, 4.97 x 10-4 and 9.07 x 10-2 for H2S, CH3SH and (CH3)2S respectively), and this 
provides much evidence for differing time-dependent responses of all determined oral cavity VSCs 
to the H2O placebo treatment between our participants.  
 
From this overall mixed model ANOVA analysis, the ‘Between-Participants’ factor was found to 
be very highly significant for each VSC monitored (p < 10-8 for each one). 
 
Figure 1 shows plots of mean (±95% confidence intervals, CIs) oral cavity VSC level values versus 
post-treatment time (for H2S, CH3SH and (CH3)2S) for both the oral rinse (1) treatment and the 
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negative water control one. The CIs depicted are those made across all participants, i.e. they arise 
from the incorporation of both ‘Between-Participants’ and Error (Residual) components-of-
variances, and hence they are much wider than those which are derivable from the latter 
component alone. These plots confirm that, for H2S and CH3SH, the differences observed 
between the mean 0.00 and 12.00 hr. time-point oral cavity concentrations observed were much 
greater for the oral rinse treatment classification than those observed for the H2O control one. 
 
For the model 2 ANOVA analysis performed, there were very highly significant differences 
‘Between-Treatments, -Time-Points and -Participants’ (p = 2.58 x 10-4, < 10-8 and < 10-8 
respectively). The significance and magnitude of the ‘Between-Treatments’ effect is ascribable to 
the much greater effectiveness of the oral rinse (1) formulation over that of the water control rinse 
regimen.    
 
An additional statistical analysis of the 0.00 hr. baseline time-point VSC levels alone was also 
conducted in order to determine any ‘Between-Treatment’ differences between such values, and 
for this we employed an ANOVA model, incorporating only this and the ‘Between-Participants’ 
sources of variation, together with a paired sample t test. Although there were no statistically 
significant, participant-matched differences found between the mean baseline oral cavity 
concentrations of H2S and (CH3)2S (Bonferroni-corrected p values > 0.05), that for CH3SH was (p 
= 0.015). However, MANOVA analysis found that there were no significant ‘Between-Treatment’, 
nor ‘Between-Participant’ differences between these VSC levels when considered as a multivariate 
composite (p = 0.080 and 0.138 respectively; Hotelling-Lawley’s, Pillai’s and Roy’s tests). 
Therefore, the ANOVA-detected significant difference observed between the baseline levels of 
CH3SH is not simply explicable, but is likely to arise from a type I statistical error, i.e such 
differences will occur via chance alone in 5% of such testings for each VSC variable tested at a 
significance level of 0.05, a value which will increase to an estimate of 15% for a total of 3 such 
variables included without the incorporation of a false discovery rate correction factor.      
 
As expected, there was also a highly significant random effects ‘Between-Participant’ random 
effects component of variance for both H2S and CH3SH concentrations (p = 6.47 and 1.45 x 10
-3 
respectively), although not for (CH3)2S (p > 0.05).        
 
Analysis-of-variance of the datasets using the model 3 ANOVA model revealed that overall, the 
oral rinse formulation tested was much more effective than the negative H2O control in 
diminishing oral cavity H2S and CH3SH concentrations (p = 1.34 x 10
-5 and 4.96 x 10-4 respectively, 
Figure 2). However, for (CH3)2S, the only significant difference found ‘Between-Treatments’ was 
that at the 0.33 hr. post-administration time-point, i.e. shortly after their administration, as shown 
in Figures 1(c) and 2(c).  
 
For each VSC monitored, this analysis also revealed that there were significant Treatment x Time-
Point Interaction components of variances for H2S, CH3SH and (CH3)2S (p < 0.0001, < 0.0001 
and 0.002 respectively), observations which confirm that the nature/magnitude of the time-
dependence of the response to treatments was critically dependent on each one investigated (i.e. 
oral rinse (1) versus the H2O control, Figure 2). Although no significant ‘Between-Treatment’ effect 
was found for CH3SH in this model 2 analysis, the very highly significant Treatment x Time-Point 
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interaction component of variance for this VSC revealed that such differences were markedly 
influenced by the time variable, e.g. the much higher and lower levels of it at the zero control and 
0.33 hr. time-points, respectively, for the oral rinse-treatment group. However, corresponding 
mean 0.00 hr. (pre-treatment) and 0.33 hr. time-point CH3SH levels for the H2O negative control 
group were similar to each other (and also very low when expressed relative to the corresponding 
zero control value of the oral rinse (1)-treated group), and there was no significant difference 
between these values [Figure 2(b)].    
 
These highly significant interaction effects are therefore particularly notable as differences in the 
mean responses of each VSC between the oral rinse (1) and the water placebo control treatments 
when expressed as a function of each post-treatment time-point. Indeed, these differences can be 
clearly visualised as significantly lower VSC concentrations in the oral rinse (1) treatment group at 
the 0.33, 4.00 and 8.00 hr. time-points than those observed for the negative H2O control, most 
especially those at each of these time-points for H2S, and at the 0.33 hr. one for both CH3SH and 
(CH3)2S. Moreover, for H2S and (CH3)2S, there were also very highly significant Treatment x 
Participant interaction effects (p < 0.0001 for each VSC), an observation which provides evidence 
that the response to each treatment differs markedly for at least some of the study participants 
(i.e., as expected, there is a non-additive response to treatment). There was no significant 
contribution of the Treatment x Participant interaction effect towards variation in the CH3SH VSC 
parameter. 
 
However, the statistical significance of mean differences in VSC levels at the 12.00 hr. diurnal 
time-point according to our model 3 analysis was manifested by the highly significant interaction 
sources of variation observed. For example, for H2S, there were very highly significantly higher 
levels of this VSC in the H2O negative control group at this final time-point, but these were only 
observed for n = 3 of the participants (these participants all had very similar baseline 0.00 hr. H2S 
concentration values at the 0.00 hr. baseline time-point for both the oral rinse (1) and H2O control 
group regimens). No statistically significant, participant-focused ‘Between-Treatment’ differences 
between the 12.00 hr. time-points were observed for all the remaining participants.  
 
The Table lists mean percentage changes expressed relative to the baseline 0.00 hr. mean 
concentrations of H2S, CH3SH and (CH3)2S at increasing trial time-points for both the oral rinse 
(1) and H2O control treatment groups. Clearly, these percentage modifications are significantly 
greater for the oral rinse (1) treatment group for all three VSCs throughout the 0.33-8.00 hr. time-
points, but less so at the 12.00 hr. one. 
 
Finally, for our model 4 analysis, mean±95% CI decreases in the H2S, CH3SH and (CH3)2S VSC 
concentrations between the 0.00 hr. control and 12.00 hr. post-administration time-points were 
67±6.0, 57±0.9 and 12±3.7 ppb, respectively, for the oral rinse treatment, and 39±6.0, 20±1.0 and 
18 ppb±3.8, respectively, for the negative water placebo control (Figure 3). Moreover, ‘Between-
Treatment’ differences between these mean decreases were extremely significant at the p < 10-8 
level for both H2S and CH3SH. However, that observed for CH3SH is at least partially explicable 
by the significantly higher 0.00 hr. baseline concentration value observed for the oral rinse (1) 
treatment regimen. Moreover, the corresponding ‘Between-Treatment’ difference observed for 
reductions observed in mean (CH3)2S concentrations was found not to be significant. For H2S, the 
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above difference corresponds to a 12. hr. time-point longevity reduction of > 80% for treatment 
with oral rinse (1); the corresponding 12 hr. decrease observed for the negative water control group 
was only 55%.  
 
Multivariate analysis of our experimental dataset at the baseline 0.00 hr. (control) time-point via 
PCA demonstrated that the 3 VSC variables were effectively segregated into two clear orthogonal 
(i.e. uncorrelated) principal components (PCs), the first containing H2S and CH3SH (loading 
vectors 0.86 and 0.88 respectively), the second (CH3)2S alone (loading vector 0.99). These results 
are fully consistent with the sources of these malodorous agents, i.e. H2S and CH3SH arise from 
the oral environment, whereas (CH3)2S has a non-oral source (predominantly blood).  
 
Consistent with these results, a Pearson correlation analysis of the untransformed baseline 0.00 hr. 
time-point VSC concentrations confirmed that there was a highly significant, albeit moderate, 
linear correlation between oral cavity H2S and CH3SH levels (r = 0.52, p =2.07 x 10
-5 ), but not 
between H2S and (CH3)2S (r = 0.19, ns), nor CH3SH and (CH3)2S (r = 0.14, ns) concentrations 
(Figure 4), data consistent with the above PCA analysis and also indicating an independent (non-
oral) source for (CH3)2S (corresponding partial correlation coefficient values for these data were  
0.51, 0.15 and 0.04 respectively).  
 
Cross-over correlations between participants’ 0.00 hr. baseline VSC concentration data of the oral 
rinse treatment sampling group with those of the H2O control group at this time-point were strong 
for both H2S (r = 0.44, p = 0.014) and CH3SH (r = 0.66, p = 7.94 x 10
-5), but much less so for 
(CH3)2S (r = 0.25, p = 0.046), as might be expected from its non-oral source.  
 
We also performed a full correlation analysis of our datasets in order to determine if there were 
any significant relationships between the concentrations of each VSC at the zero baseline time-
point and that at the 12 hr. trial completion one, and this confirmed that for both treatment groups 
combined, there were weak but nevertheless significant correlations between these time-points for 
oral cavity H2S (r = 0.250 p = 5.91 x 10
-3) and (CH3)2S (r = 0.315, p = 4.58 x 10
-4) levels, but not 
for those of CH3SH (r = 0.00, ns) at these two extremes, and this demonstrates at least some 
consistency in these H2S and CH3SH concentrations between participants recruited to the study. 
  
Pearson correlation coefficients for these relationships were also determined for each treatment 
group, and found that both time-point sets of oral cavity H2S and (CH3)2S concentrations were 
significantly related (r = 0.26 and 0.37, p = 0.045 and 3.46 x 10-3 respectively) for the negative H2O 
control group, and also for the oral rinse (1)-treated group (r = 0.29 and 0.22, p = 0.025 and 9.69 
x 10-2 respectively). There were no significant correlations for CH3SH levels in either of these 
groups.       
 
4. DISCUSSION 
 
For H2S, CH3SH and (CH3)2S, the oral rinse formulation (1) explored here exerted very highly 
significant VSC-neutralising activities which were of a significantly greater magnitude than those 
observed with the water placebo control rinse (especially for H2S and CH3SH). Since reported 
threshold concentrations of malodorous objectionabilities (TCMOs) are 95, 12 and 24 ppb for 
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H2S, CH3SH and (CH3)2S respectively [31], it is clear from the investigations described here that 
application of this oral rinse product successfully retains the mean level of each of these VSCs 
below these objectionable threshold values for periods of up to 12.00 hr. post-application. Indeed, 
the mean 12 hr. time-point reductions in oral cavity VSC concentrations observed in participants 
using this oral rinse formulation were 70 and as much as 77% of the above TCMO values for H2S 
and CH3SH respectively; this clearly is a very significant observation regarding the longevity of the 
VSC-neutralising activities of this product.   
 
It should also be noted that the overall, total zero pre-treatment time-point mean oral cavity air 
H2S, CH3SH and (CH3)2S concentrations of our randomly selected 24-55 year age participant 
population were 71, 39.5 and 26.5 ppb respectively, values which are either close to (H2S) or exceed 
(CH3SH and (CH3)2S) these TCMOs. These data clearly indicate that oral malodour has a high 
incidence within the human population sampled.       
 
The reductions, albeit lower ones (with also smaller numbers of statistically significant ones) 
recorded in oral cavity VSC levels subsequent to participants receiving the water placebo treatment 
were only observed at or subsequent to the 4.00 hr. post-application time-point, and are not 
unexpected. Indeed, these differences are likely to arise from diurnal variation in these values, 
which represents a significant source of variation for oral cavity VSC concentrations [32]. Indeed, 
although saliva effectively serves to remove oral cavity bacteria, the production of this biofluid is 
greatly diminished during the night, and therefore there are corresponding increases in the 
numbers of such residual microbes, together with their metabolic rates [33,34]. Hence, tongue 
biofilm- and plaque-harbouring bacteria generate higher concentrations of VSCs throughout the 
night, and this, in turn, leads to ‘morning bad breath’. Oral hygiene regimens instigated in the 
morning will primarily reduce oral cavity VSC levels which then begin to increase again prior to 
meals [35]; surprisingly, it has been reported that such eating episodes serve to either decrease VSC 
levels, or alternatively exert little or no effect [35]. However, oral cavity VSC levels increase 
between eating and/or drinking episodes, but such levels rarely exceed those developed overnight.  
 
Notwithstanding, despite the markedly higher VSC level reductions observed in the oral rinse (1) 
treatment group over those of the H2O control one, it should be noted that the only significant 
‘Between-Treatment’ differences between the mean 12.0 hr. time-point oral cavity concentration 
values of these for all VSCs evaluated were those observed in small numbers of participants, a 
consequence of the significant Participant x Treatment interaction effect in our Model 3 analysis, 
and this may be explicable by their diurnal variation and potential reductions in their 
concentrations induced by the consumption of an evening meal at a time-point close to the final 
12.00 hr. sampling and testing one (exactly 10 pm) by a significant or even substantial proportion 
of them.  
 
A further consideration is that all VSC level values were virtually zero at this 12.00 hr. time-point 
in both treatment groups for CH3SH. Again, this observation may be ascribable to diurnal 
variation, possibly featuring meal consumption activities close to the final 12 hr. VSC measurement 
time-point. However, the percentage reduction in the oral cavity concentration of this VSC 
observed in the matched oral rinse treatment group over that of the negative H2O control one 
(according to our model 4 experimental design) was resoundingly significant (p <  
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10-8).   
The oxidative consumption of the VSCs H2S, CH3SH and (CH2)2S, together with their essential 
amino acid precursors L-cysteine and L-methionine, serves as a major mechanism of action for 
the chlorine dioxide precursor chlorite anion present in the oral rinse formulation investigated here 
(displayed for CH3SH and (CH3)2S in equations 5 and 6 respectively). Indeed, orally-generated H2S 
and CH3SH are produced from these amino acids in key metabolic pathways operating in gram-
negative bacteria. 
 
4CH3SH + ClO2
- → 2CH3S-SCH3 + Cl
- + 2H2O        (5) 
 
2CH3SCH3 + ClO2
- → 2CH3SOCH3 + Cl
-                  (6)     
 
Our group have previously employed a less specific halimeter monitoring device to evaluate the 
relative effectiveness of 6 oral healthcare products in diminishing oral cavity VSC concentrations 
[36]. This study involved a mixed model 3-factor factorial experimental design involving 6 
volunteers, 7 treatment regimens (including a water placebo), and 5 VSC monitoring time-points 
(0.00-5.29 hr.), and from the results acquired it was concluded that oral rinses containing 
oxyhalogen oxidants such as chlorite anion, and, in principle, also chlorine dioxide (ClO2
●) derived 
therefrom in vivo, may indeed provide a useful therapeutic strategy for the treatment of oral 
malodour.  
Earlier evidence for the oral malodour-neutralising properties of chlorite anion/chlorine dioxide, 
and any of the latter derived from the former in vivo, has been provided by Tozentich (1977) [1], 
who revealed that the therapeutic application of an oral rinse formulation containing only 0.01% 
(w/v) of these agents significantly decreased VSC levels in early morning mouth air samples 
collected from human participants with highly objectionable concentrations of these malodorous 
agents.   
However, one limitation of our experimental design was the exclusion of other oral rinse 
formulations, including a positive control product formulation. However, the oxyhalogen oxidant 
present in oral rinse product (1) has already been proven to be effective in combating oral 
malodour. Indeed, Shinada et al. [29] compared the effectiveness of two oral rinses against oral 
cavity VSC levels, one containing ClO2
-, the second without this active ingredient. These 
researchers found that the former product significantly reduced mouth air H2S, CH3SH and 
(CH3)2S levels and hence improved oral malodour, and that such effects were prolonged, but only 
for a 4.0 hr. period. In a related study, the ability of another ClO2
--containing mouthrinse product 
to combat oral malodour for periods of up to 96 hr. post-rinsing were evaluated [37], and results 
arising therefrom revealed that VSC concentrations, as monitored by organoleptic measurements 
and an early total sulphide and thiol monitoring device, showed that VSC levels in the test (oral 
rinse receiving) group attained minimal levels at the 8 her. post-rinsing time-point, and these 
observations are consistent with ours, although such minimal levels were maintained up to a 12 
hr. time-point in this study.  
Therefore, the VSC-neutralising capacity of the oral rinse product tested here can be rationalised 
with special reference to its chemical composition, e.g., chlorine dioxide and its chlorite anion 
precursor, which are both highly cidal towards odourigenic micro-organisms, and/or have the 
ability to directly oxidise VSCs to non-malodorous products.  
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The somewhat weaker VSC-neutralising actions of the oral rinse (1) formulation towards dimethyl 
sulphide, (CH3)2S, are presumably ascribable to the source of this VSC, i.e. its origin is outside of 
the mouth, and predominantly arises from blood [1]. Hence, the capacity of the active oral rinse 
agent (1) evaluated here (specifically chlorite at a level of 0.10% (w/v)) to react with and hence 
modulate or attenuate oral cavity levels of this particular VSC will be expected to be less so than 
those with H2S and CH3SH, which arise from the bacterial degradation of both cysteine and 
methionine within the oral cavity. 
 
These results are comparable to those achieved in a study featuring an alternative oral rinse product 
containing low levels of chlorhexidine and zinc ions (Zn2+), and in which morning breath odour 
was successfully suppressed throughout a 12 hr. period, both with and without a challenge with 
oral cavity VSC-promoting L-cysteine [38]. The duration of the efficacy of this product observed 
was attributed to the involvement of a synergistic effect between the two active agents therein. 
However, this investigation focused on the actions of this oral rinse overnight during sleep 
episodes, and VSC measurements (limited to those of H2S and CH3SH) were only made at the 
zero control and post-12 hr. time-points. In contrast, our study was targeted on daily diurnal VSC 
measurements, and a total of 9 oral cavity VSC determinations were made on each participant at 
increasing time-points (0-12 hr.) for each treatment tested, i.e. oral rinse (1) versus the negative H2O 
control. Moreover, our experiments also featured the simultaneous measurement of 3 rather than 
2 VSCs. 
 
A more recent study [39] explored the long-term activities of an oral rinse formulation   containing 
a mixture of 0.30% (w/w) zinc acetate and 0.025% (w/w) chlorhexidine, against intra-oral 
malodour. This double-blind, controlled cross-over study, which involved three treatments 
administered 12 hr. apart, i.e. both morning and evening on consecutive days, and with a 5 day 
washout period between such treatments, found that mean H2S, CH3SH and (CH3)2S 
concentrations were significantly reduced by the administration of this product for evaluations 
conducted either overnight or during daylight hours. This effect prevailed throughout a 12 hr. 
time-point. Moreover, this oral rinse was also found to exert a significant reduction in the mean 
organoleptic score values of participants during the overnight monitoring period.     
 
The results acquired here also have a high level of clinical significance, since there is now much 
evidence available that VSCs, which are extremely toxic to tissues at very low concentrations, are 
involved in the pathogenesis of periodontal diseases and further inflammatory conditions 
(reviewed in [40]). Moreover, the generation of high concentrations of CH3SH appears to be 
restricted to periodontal pathogenic bacteria. Protein biosynthesis by cultured human gingival 
fibroblasts is also inhibited by these VSCs, and CH3SH has been found to enhance the permeability 
of the intact mucosa and promote the generation of cytokines, which are clearly linked to 
periodontal diseases. Additionally, further in vitro investigations have revealed that exposure of cells 
to CH3SH gives rise to a diminished level of collagen biosynthesis, and also a higher level of its 
degradation, together with the accumulation of poorly-cross-linked collagen precursors, the latter 
also being particularly susceptible to proteolysis. Hence, these malodorous VSCs have the capacity 
to exert clinically significant adverse effects on the local immune response of periodontal tissues 
towards plaque antigens, and also on extracellular matrices [40] loc cit.  
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Indeed, periodontal diseases give rise to elevated VSC concentrations in mouth air, and those of 
CH3SH have been found to be significantly enhanced in patients with periodontal disease over 
those of an orally healthy control group [41]. Although the current investigation was performed 
with orally healthy participants, results acquired indicate that the ClO2
--containing oral rinse 
formulation tested here will also successfully exert such VSC-neutralising actions in periodontal 
disease patients.   
 
Finally, to the best of our knowledge, this is the first study reporting a multivariate statistical 
analysis of baseline oral cavity VSC levels collected from pre-fasted human participants, and this 
involved a full PCA strategy performed on a trivariate VSC dataset. Results from this analysis were 
fully consistent with the differing biological sources of a composite H2S- and CH3SH-loaded 
multivariate PC arising from the oral environment, and which was shown to be clearly distinct 
from a second PC containing blood source (CH3)2S alone.    
 
 
5. CONCLUSIONS 
  
An oral rinse formulation containing the chlorine dioxide precursor sodium chlorite at a 
concentration of 0.10% (w/v) serves as a very effective intra-oral neutraliser and/or consumer of 
VSCs, an observation which strongly supports its employment for controlling oral malodour. This 
efficacy is prolonged for periods of 12 hours, and the mechanisms involved in this process are 
likely to feature (1) the direct chemical consumption of VSCs and their salivary sulphur-containing 
amino acid precursors, and/or (2) the bactericidal actions of chlorite anion against gram-negative 
bacteria responsible for VSC generation. These results have a high level of clinical significance in 
view of the established highly toxic actions of VSCs, and their striking relationships to the 
pathogenesis of periodontal diseases.        
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Table 
 
Treatment 
Time 
(hr.) 
Mean [H2S] 
±95% 
CIs/ppb 
Mean 
[CH3SH] 
±95% 
CIs/ppb 
Mean 
[(CH3)2S] 
±95% 
CIs/ppb 
Oral rinse (1) 
0.00 100 100 100 
0.33 26.2±9.5 5.26±4.2 45.1±21.2 
4.00 23.8±7.3 7.0±5.1 77.4±22.6 
8.00 21.1±8.0 2.0±6.1 61.9±24.4 
12.00 27.6±14.3 2.5±1.8 48.5±18.9 
H2O control 
0.00 100 100 100 
0.33 109.9±33.5 83.6±46.7 107.3±32.2 
4.00 66.8±19.9 13.7±7.7 77.7±21.8 
8.00 58.2±15.0 27.5±41.8 74.0±25.6 
12.00 31.1±15.4 4.6±6.1 38.9±22.5 
 
Table. Mean±95% confidence intervals (CIs) modifications in oral cavity VSC levels at the 0.33, 
4.00, 8.00 and 12.00 hr. time-points expressed as a percentage of those observed at the 0.00 hr. 
baseline ones for both the oral rinse (1) and H2O negative control treatment regimens.  
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Figure Legends 
 
Figure 1. Plots of mean (±95% CIs) oral cavity (a) H2S, (b) CH3SH and (c) (CH3)2S concentrations 
versus post-treatment time for both the oral rinse (1) treatment (red) and the negative water control 
one (blue). The CIs represent those made across all participants, i.e. they arise from the 
incorporation of both ‘Between-Participants’ and Error (Residual) components-of-variances.  
 
Factorial statistical analysis according to our model 1 ANOVA experimental design revealed that 
there were extremely significant decreases in the 0.00 hr. baseline time-point concentrations of 
H2S and CH3SH observed at 0.33, 4.00, 8.00 and 12.00 hr. post-rinsing with product (1) (p = 1.81 
x 10-13 and 2.54 x 10-17 respectively), but only significant reductions in mean baseline (CH3)2S levels 
noted at 0.33, 8.00 and 12.00 hr. post-rinsing with this formulation (p = 2.57 x 10-8). For the 
negative control tap water wash, significant decreases from 0.00 hr. baseline values were observed 
only at the 4.00, 8.00 and 12.00 hr. post-rinsing time-points for both H2S and CH3SH (p < 4.11 x 
10-14 and 3.36 x 10-8 respectively), and only at the 12.00 hr. time-points for (CH3)2S (p = 1.23 x  
10-7).    
 
A more extensive statistical analysis performed according to our model 3 approach demonstrated   
that oral rinse formulation (1) was much more effective than the negative H2O control in reducing 
oral cavity H2S and CH3SH levels (p = 1.34 x 10
-5 and 4.96 x 10-4 respectively). For (CH3)2S, the 
only significant difference found ‘Between-Treatments’ was that at the 0.33 hr. post-rinsing time-
point. This analysis model also showed that there were significant Treatment x Time-Point 
interaction components of variances for H2S, CH3SH and (CH3)2S (p < 0.0001, < 0.0001 and 0.002 
respectively); for H2S and (CH3)2S, there were also very highly significant Treatment x Participant 
interaction effects (p < 0.0001 for each VSC) 
 
‘Between-Treatment’ differences observed between the 12.00 hr. time-point values were 
manifested by those observed only in selected participants, in accordance with the statistical 
significance of the Treatment x Participant interaction effect noted.     
 
Figure 2. Plots of glog-transformed and normalised mean oral cavity VSC levels (with associated 
95% CIs) versus sampling time-point for (a) H2S, (b) CH3SH and (c) (CH3)2S following treatment 
with the H2O negative control rinse (blue) and oral rinse (1) (red). 95% CIs were computed 
according to model 2. The statistical significance of these effects is outlined in the legend to 
Figure 1.  
 
Figure 3. Plot of mean (± 95% CIs) differences in oral cavity H2S (green), CH3SH (brown) and 
(CH3)2S (blue) concentrations between the 0.00 hr. pre-treatment and 12.00 post-treatment time-
points observed for the negative water placebo control (left-hand side) and oral rinse (1) (right-
hand side). Between-Treatment’ differences between these mean decreases were extremely 
significant for both H2S and CH3SH (p < 10
-8), but were not significant for (CH3)2S.  
 
Figure 4. PCA scores plot of PC2 versus PC1 for the 0.00 hr. baseline VSC concentration dataset 
(involving two treatment regimen groups each containing n = 30 matched participants). PC 
loadings vectors were 0.856 and 0.879 for H2S and CH3SH, respectively, on PC1, and 0.994 for 
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(CH3)2S on PC2. Eigenvalues (i.e. the mean number of variables loading on a PC) for the 
corresponding unrotated PCA performed were 1.61 and 0.91 for PC1 and PC2 respectively. PCs 
1 and 2 accounted for 50.48 and 33.65% of the total model variance respectively. Line colour 
codings: green, H2S; purple, CH3SH; blue, (CH3)2S.   
 
Figure 5. Correlation matrix diagram displaying a moderate but highly significant correlation 
between 0.00 hr. time-point morning baseline oral cavity H2S and CH3SH concentrations (n = 60 
in total, 30 in each of the two treatment groups), but not between those of H2S and (CH3)2S, nor 
CH3SH and (CH3)2S. The left-hand and top axis tab displays results arising from agglomerative 
hierarchal clustering (AHC) analysis of this dataset, which confirms the significant clustering of 
H2S and CH3SH levels, and also the independence of those of (CH3)2S.       
 
      
 
 
 
 
 
 
